Pelthos Swings to $21.7M Loss Post-Merger, ZELSUVMI Drives Revenue

Ticker: PTHS · Form: 10-Q · Filed: 2025-11-13T00:00:00.000Z

Sentiment: mixed

Topics: Biotechnology, Pharmaceuticals, Molluscum Contagiosum, FDA Approval, Mergers and Acquisitions, PIPE Financing, Net Loss

Related Tickers: PTHS, LIGD

TL;DR

**PTHS is burning cash fast post-merger, but ZELSUVMI's launch revenue offers a glimmer of hope if they can control expenses.**

AI Summary

Pelthos Therapeutics Inc. (PTHS) reported a significant operational shift and financial performance for the nine months ended September 30, 2025, following its merger with LNHC, Inc. on July 1, 2025. The company generated total revenue of $7.406 million, primarily from net product revenues of $7.112 million for ZELSUVMI, a product commercially launched in July 2025. This is a substantial increase from zero revenue in the prior year period. However, the company experienced a net loss of $21.655 million for the nine months ended September 30, 2025, compared to a net loss of $6.029 million in the same period of 2024, driven by a surge in selling, general, and administrative expenses to $23.984 million from $4.853 million. Cash and cash equivalents dramatically increased to $14.203 million as of September 30, 2025, from $513 thousand at December 31, 2024, largely due to $27.384 million in proceeds from a PIPE financing. Total assets grew from $1.369 million to $126.433 million, reflecting the acquisition of LNHC, Inc., which brought in intangible assets of $32.521 million and goodwill of $30.625 million. The company's strategic outlook is centered on commercializing ZELSUVMI and developing its clinical-stage NaV1.7 assets.

Why It Matters

This 10-Q reveals Pelthos Therapeutics' transformation into a commercial-stage biopharma company with the acquisition of LNHC, Inc. and the launch of ZELSUVMI. For investors, the significant increase in net loss to $21.655 million, despite new revenue, highlights the high burn rate associated with commercialization and integration, demanding close scrutiny of future profitability pathways. Employees of the newly merged entity face the challenge of integrating operations and scaling ZELSUVMI's market penetration. Customers, particularly those with molluscum contagiosum, gain access to a new FDA-approved treatment. The broader market will watch if PTHS can effectively compete in the dermatology space, especially against established players, given its substantial increase in selling, general, and administrative expenses.

Risk Assessment

Risk Level: high — The company reported a net loss of $21.655 million for the nine months ended September 30, 2025, and an accumulated deficit of $43.130 million, indicating significant ongoing losses. Selling, general and administrative expenses surged to $23.984 million, far exceeding the $7.406 million in total revenue, demonstrating a high cash burn rate relative to current income.

Analyst Insight

Investors should monitor Pelthos Therapeutics' next few quarters closely for signs of improved cost control and ZELSUVMI's market adoption. While the PIPE financing provided a cash infusion, sustained losses could necessitate further dilution. Consider a 'wait and see' approach to assess if revenue growth can outpace the escalating operating expenses.

Financial Highlights

debt To Equity
N/A
revenue
$7.406M
operating Margin
N/A
total Assets
$126.433M
total Debt
N/A
net Income
-$21.655M
eps
N/A
gross Margin
N/A
cash Position
$14.203M
revenue Growth
N/A

Revenue Breakdown

SegmentRevenueGrowth
ZELSUVMI Product Revenue$7.112MN/A
Total Revenue$7.406MN/A

Key Numbers

Key Players & Entities

FAQ

What was Pelthos Therapeutics Inc.'s total revenue for the nine months ended September 30, 2025?

Pelthos Therapeutics Inc. reported total revenue of $7.406 million for the nine months ended September 30, 2025. This revenue was primarily driven by net product revenues of $7.112 million from ZELSUVMI, which was commercially launched in July 2025.

How did Pelthos Therapeutics Inc.'s net loss change from 2024 to 2025?

Pelthos Therapeutics Inc.'s net loss significantly increased to $21.655 million for the nine months ended September 30, 2025, compared to a net loss of $6.029 million for the same period in 2024. This widening loss is largely attributable to increased operating expenses post-merger.

What was the impact of the LNHC, Inc. acquisition on Pelthos Therapeutics Inc.'s balance sheet?

The acquisition of LNHC, Inc. on July 1, 2025, dramatically increased Pelthos Therapeutics Inc.'s total assets from $1.369 million at December 31, 2024, to $126.433 million at September 30, 2025. Key additions included $32.521 million in intangible assets and $30.625 million in goodwill.

What is ZELSUVMI and when was it launched by Pelthos Therapeutics Inc.?

ZELSUVMI (berdazimer) topical gel, 10.3% is a commercial product for the treatment of molluscum contagiosum. It was approved by the U.S. Food and Drug Administration (FDA) in January 2024 and commercially launched by Pelthos Therapeutics Inc. in July 2025.

How much cash did Pelthos Therapeutics Inc. raise from its PIPE Financing?

Pelthos Therapeutics Inc. received gross proceeds of approximately $50.100 million from its PIPE Financing, consisting of approximately $50.000 million in cash and the conversion of approximately $100 thousand of principal and interest from an outstanding convertible note. Net proceeds from the PIPE financing were $27.384 million.

What were Pelthos Therapeutics Inc.'s selling, general and administrative expenses for the nine months ended September 30, 2025?

For the nine months ended September 30, 2025, Pelthos Therapeutics Inc.'s selling, general and administrative expenses were $23.984 million. This represents a significant increase from $4.853 million in the same period of 2024, reflecting the costs associated with commercializing ZELSUVMI and integrating LNHC.

What is the strategic focus of Pelthos Therapeutics Inc. after the July 1, 2025 merger?

Following the July 1, 2025 merger, Pelthos Therapeutics Inc.'s strategic focus includes commercializing ZELSUVMI, leveraging its facility and expertise to manufacture the API for ZELSUVMI, and advancing its clinical-stage NaV1.7 assets, which target pain receptors.

What was the number of common shares outstanding for Pelthos Therapeutics Inc. as of November 7, 2025?

As of November 7, 2025, the number of shares of Pelthos Therapeutics Inc.'s common stock outstanding was 3,061,681. This reflects significant share issuance activities, including those related to the LNHC acquisition and PIPE financing.

What are the primary risks highlighted by Pelthos Therapeutics Inc.'s financial performance?

The primary risks highlighted by Pelthos Therapeutics Inc.'s financial performance include a high cash burn rate, evidenced by a net loss of $21.655 million and selling, general and administrative expenses of $23.984 million, significantly exceeding revenue. The accumulated deficit of $43.130 million also points to ongoing profitability challenges.

How did the merger with LNHC, Inc. affect Pelthos Therapeutics Inc.'s cash flow from investing activities?

The acquisition of LNHC, Inc. resulted in $2.761 million in cash flow from investing activities for Pelthos Therapeutics Inc. for the nine months ended September 30, 2025. This was the sole item contributing to net cash provided by investing activities during that period.

Risk Factors

Industry Context

The biopharmaceutical industry is characterized by high R&D costs, lengthy development cycles, and significant regulatory hurdles. Companies like Pelthos Therapeutics operate in a competitive landscape where successful commercialization of novel therapies is crucial for survival and growth. The focus on specialized products like ZELSUVMI and pipeline assets targeting specific biological pathways reflects a common strategy to address unmet medical needs.

Regulatory Implications

Pelthos Therapeutics faces ongoing regulatory scrutiny typical of pharmaceutical companies. The commercialization of ZELSUVMI and the development of its NaV1.7 assets require adherence to strict FDA guidelines and post-market surveillance. Any adverse findings or changes in regulatory requirements could impact product viability and market access.

What Investors Should Do

  1. Monitor ZELSUVMI's market penetration and sales trajectory closely, as it is the primary revenue driver.
  2. Evaluate the company's ability to manage increased operating expenses and move towards profitability.
  3. Assess the progress and risks associated with the development of the NaV1.7 pipeline assets.
  4. Analyze the integration success of LNHC, Inc. and the realization of synergies post-merger.
  5. Observe future financing activities and cash burn rate given the current accumulated deficit.

Key Dates

Glossary

ZELSUVMI
A pharmaceutical product commercialized by Pelthos Therapeutics Inc. (The primary driver of the company's current revenue.)
NaV1.7 assets
Clinical-stage drug candidates targeting the NaV1.7 ion channel, potentially for pain management. (Represents a key part of the company's future development pipeline.)
PIPE financing
Private Investment in Public Equity, a type of financing where private investors purchase stock directly from a publicly traded company. (Provided a significant cash infusion ($27.384 million) to bolster the company's balance sheet.)
Goodwill
An intangible asset that arises when one company acquires another for a price greater than the fair market value of its identifiable net assets. (A substantial component ($30.625 million) of the assets acquired in the LNHC merger.)
Intangible Assets, net
Non-physical assets that have value, such as patents, trademarks, and customer lists, net of accumulated amortization. (Includes assets acquired from LNHC, Inc. ($32.521 million), contributing to the post-merger balance sheet.)
Accumulated Deficit
The cumulative net losses of a company since its inception, reducing total stockholders' equity. (Indicates the company's historical unprofitability ($43.130 million as of Sept 30, 2025).)

Year-Over-Year Comparison

Compared to the prior year period, Pelthos Therapeutics has undergone a dramatic transformation. Total revenue has shifted from $0 to $7.406 million, driven by the ZELSUVMI launch post-merger. However, this revenue growth is accompanied by a significant increase in net loss, from $6.029 million to $21.655 million, largely due to a surge in SG&A expenses from $4.853 million to $23.984 million. Total assets have exploded from $1.369 million to $126.433 million, reflecting the LNHC acquisition, while cash has increased substantially from $513 thousand to $14.203 million due to a PIPE financing.

Filing Stats: 4,834 words · 19 min read · ~16 pages · Grade level 17.5 · Accepted 2025-11-13 06:46:35

Key Financial Figures

Filing Documents

: FINANCIAL INFORMATION

PART I: FINANCIAL INFORMATION

Financial Statements (unaudited)

Item 1. Financial Statements (unaudited) 1 Condensed Consolidated Balance Sheets 2 Condensed Consolidated Statements of Operations 3 Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficit) 4 Condensed Consolidated Statements of Cash Flows 6 Notes to Condensed Consolidated Financial Statements 8

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 41

Quantitative and Qualitative Disclosures About Market Risk

Item 3. Quantitative and Qualitative Disclosures About Market Risk 66

Controls and Procedures

Item 4. Controls and Procedures 66

OTHER INFORMATION

PART II. OTHER INFORMATION

Legal Proceedings

Item 1. Legal Proceedings 68

Risk Factors

Item 1A. Risk Factors 68

Unregistered Sales of Equity Securities and Use of Proceeds

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 68

Defaults Upon Senior Securities

Item 3. Defaults Upon Senior Securities 69

Mine Safety Disclosures

Item 4. Mine Safety Disclosures 69

Other Information

Item 5. Other Information 69

Exhibits

Item 6. Exhibits 69

SIGNATURES

SIGNATURES 73 PART I: FINANCIAL INFORMATION Item 1. Financial Statements 1 PELTHOS THERAPEUTICS INC. CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands, except share and per share amounts) September 30, 2025 December 31, 2024 (Unaudited) ASSETS Cash and cash equivalents $ 14,203 $ 513 Restricted cash, current 50 — Accounts receivable, net 7,988 — Inventory, net 24,096 — Prepaid expenses and other current assets 3,424 856 Total current assets 49,761 1,369 Property and equipment, net 10,174 — Operating lease right-of-use assets, net 3,352 — Intangible assets, net 32,521 — Goodwill 30,625 — Total assets $ 126,433 $ 1,369 LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) Accounts payable $ 5,666 $ 1,897 Accrued expenses 11,890 — Operating lease liabilities, current portion 631 — Deferred revenue, current portion 1,019 — Loan payable, net of debt discount — 2,054 Loan payable - related party, net of debt discount — 132 Other liabilities 5,562 — Total current liabilities 24,768 4,083 Operating lease liabilities, net of current portion 2,849 — Deferred revenue, net of current portion 1,522 — Deferred income tax liability 12,866 — Other long-term liabilities 26,175 — Total liabilities 68,180 4,083 Commitments and contingencies (Note 11) — STOCKHOLDERS' EQUITY (DEFICIT) Preferred stock Series A, $ 0.0001 par value, 150,000 shares authorized, 57,568 shares issued and outstanding as of September 30, 2025 and 700,000 shares authorized, no shares issued or outstanding as of December 31, 2024, respectively — — Preferred stock Series C, $ 0.0001 par value, 5,000 shares authorized, 2,600 and 2,600 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively — — Common stock, $ 0.0001 par value, 200,000,000 shares authorized, 3,090,729 and 610,389 shares issued and outstanding as of September 30, 2025 and December 31, 2024, r

View on Read The Filing